Výsledky vyhledávání - "Sylvie Jacod"

Identification of a Clinical-Grade Maturation Factor for Dendritic Cells

Autor: Alessandra Nardin, Jean-Pierre Abastado, Aurélie Boyer, Sylvie Jacod, Claire Boccaccio, Andrew Kaiser

Publikováno v: Journal of Immunotherapy. 25:88-96

Dendritic cells (DC) are essential for the generation of primary adaptive immune responses, but their full immunostimulatory capacities are only reached upon maturation. The authors compared several clinical-grade adjuvants of bacterial origin to det

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bc95e132213ba8ea0ca26cccdb8f89a
https://doi.org/10.1097/00002371-200201000-00010

Zobrazit plný text záznamu

Regulatory dysfunction of the interleukin-7 receptor in CD4 and CD8 lymphocytes from HIV-infected patients--effects of antiretroviral therapy

Autor: Arnaud Fontanet, Jean-Hervé Colle, Jacques Thèze, Jean-Louis Moreau, Sylvie Jacod, Marcel Joussemet, Olivier Lambotte, Jean-François Delfraissy

Publikováno v: Journal of acquired immune deficiency syndromes (1999). 42(3)

Despite an increase in plasma IL-7 levels, the CD4 T-cell pool decrease progressively in HIV-infected patients. Here we report on our tests to check the hypothesis that defects in the IL-7 receptor system might be involved in this phenomenon. The cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::374e5a577c49df9a8c80032ec5a55017
https://pubmed.ncbi.nlm.nih.gov/16810123

Zobrazit plný text záznamu

A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial

Publikováno v: Journal of Clinical Oncology. 32:5529-5529

5529 Background: IGF signaling has been implicated in the pathogenesis and progression of ovarian cancer (OC). Ganitumab (GAN; AMG 479) is an investigational, fully human, monoclonal antibody inhib...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95ddb28b6b9cf067401584938882ef48
https://doi.org/10.1200/jco.2014.32.15_suppl.5529

Zobrazit plný text záznamu

A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer

Autor: Robert D. Loberg, Seamus O'Reilly, Matthias W. Beckmann, Vincent Houe, Gottfried E. Konecny, Dennis J. Slamon, Lorraine Elit, Sylvie Jacod, John A. Glaspy, Beth Y. Karlan, Paul Cottu, Linda D. Bosserman, Diane Provencher, Isabelle Ray-Coquard, Paul Haluska

Publikováno v: Journal of Clinical Oncology. 31:5515-5515

5515 Background: IGF signaling has been implicated in the pathogenesis and progression of ovarian cancer (OC). Single agent activity and safety of ganitumab (AMG 479), a fully human monoclonal antibody against IGF-1R that blocks binding of IGF1 and I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75eb98a4e48863a0ae0ae207107fb218
https://doi.org/10.1200/jco.2013.31.15_suppl.5515

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání